CHF-6467 exhibits neuroprotective effects in experimental models of neonatal HIE
Oct. 18, 2024
Researchers from Chiesi Farmaceutici SpA published new clinical data for CHF-6467, a recombinant modified form of human nerve growth factor (NGF), being evaluated for the treatment of neonatal hypoxic-ischemic encephalopathy (HIE).